Home page

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

Release time:

2026-03-27

Nanolattix Chairman Qu Zhican Invited to Attend 3rd Radiopharmaceutical Development Summit, Collaborates to Shape RDC Innovation Landscape

On March 26-27, 2026, the "2026 Future XDC Conference" grandly opened at the Chengdu Medical City in China. As a representative of innovative strength in the biopharmaceutical field, Dr. Qu Zhican, Chairwoman of Nanolattix, was invited to attend the conference, injecting new momentum into the industry's development from the forefront of innovation.

On March 26, during the "RDC Source Innovation" session of the Future Radiopharmaceuticals Forum, Dr. Qu Zhican delivered a keynote speech titled "Next-Generation Precision Therapy: Pioneering Exploration of Bispecific ADC and RDC Combination Therapies." She systematically elucidated the innovative rationale behind combining RDC and ADC therapies and shared the R&D progress of Nanolattix's bispecific ADC-B836 targeting cutting-edge targets such as Tissue Factor (TF) and HER2. This drug is expected to offer a novel approach to overcoming the challenges of tumor heterogeneity and drug resistance, potentially becoming a key breakthrough in future precision therapy.
Dr. Qu Zhican also highlighted Nanolattix's independently developed first theranostic radiopharmaceutical conjugate (RDC) RT01. This drug shares the same antibody as Nanolattix's ADC drug T320, achieving theranostic synergy, and has successfully entered an Investigator-Initiated Trial (IIT). This thoroughly demonstrates how Nanolattix leverages technological innovation to advance precision therapy from the laboratory to the clinic.

The conference's scope expanded from XDC to the AXC (APC, AOC) fields, focusing on AI-driven transformations in antibody biopharmaceutical R&D and next-generation technological breakthroughs such as bispecific ADCs. During the conference, multiple high-level dialogues and ecosystem events were held concurrently. Nanolattix engaged in in-depth exchanges with industry leaders from Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Eli Lilly & Co., and other biopharmaceutical elites, discussing cutting-edge advancements and jointly driving precision medicine to new heights.